Eli Lilly and Company (LLY)
Why Eli Lilly Stock Popped on Thursday
Eli Lilly (LLY 4.07%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report.
LLY Gains on Weight Loss Drugs, F Tariff Fears, HON Split
Eli Lilly (LLY) shares ran higher following its earnings report with its weight loss drugs in focus. Ford Motor Co. (F) hit a 52-week low with tariffs from President Trump posing questions around the company's outlook.
Eli Lilly Q4 earnings beat as weight loss drug sales miss estimates
Eli Lilly and Co (NYSE:LLY) reported mixed results for the fourth quarter, with earnings outpacing estimates as revenue from its weight loss drugs Mounjaro and Zepbound fell short. Revenue surged 45% year-over-year to $13.53 billion, slightly below the $15.37 billion expected by Wall Street analysts.
Eli Lilly (LLY) Q4 Earnings and Revenues Top Estimates
Eli Lilly (LLY) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $2.49 per share a year ago.
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
On Thursday, Eli Lilly and Co LLY stock is trading higher after the company released better-than-expected fourth-quarter earnings and provided 2025 guidance.
Lilly says Mounjaro and Zepbound contributed to big revenue boost
Lilly's CEO says that the company has “tremendous momentum” entering 2025.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected. The company expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly Adjusted Profit Tops Estimates as Weight-Loss Drug Sales Fall Short
Eli Lilly (LLY) reported mostly worse-than-expected fourth-quarter results Thursday, but the drugmaker's adjusted profit came in above estimates.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results.
Eli Lilly Stock Rises After Earnings Beat
Fourth-quarter adjusted earnings of $5.32 a share beat analysts' estimates of $5.01.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but saw lower realized prices. Demand in the U.S. has far outpaced supply for Eli Lilly's incretin drugs, such as Zepbound and Mounjaro, over the last year.
Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new markets
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets.
